APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Granulocyte Macrophage Colony Stimulating Factor (GM-CSF)

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Market Outlook and Growth Opportunities 2026

Report ID 173996260429 December 2025191 pages

Choose your research edition.

Industry ResearchGranulocyte Macrophage Colony Stimulating Factor (GM-CSF) Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Industry Growth and Trends Forecast to 203292 pages · $3,450 USDMarket StructureGlobal Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032180 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) market include Nobelpharma, Partner Therapeutics, Guangzhou Baiyunshan Pharmaceutical, Harbin Pharmaceutical Group, Hainan Unipul Pharmaceutical, North China Pharmaceutical, Amoytop Biotech and Changchun GeneScience Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) market size, projected growth trends, production technologies, key applications, and end-use industries.

Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Segment by Company

Nobelpharma

Partner Therapeutics

Guangzhou Baiyunshan Pharmaceutical

Harbin Pharmaceutical Group

Hainan Unipul Pharmaceutical

North China Pharmaceutical

Amoytop Biotech

Changchun GeneScience Pharmaceutical

Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Segment by Type

Injection

Inhalation

Other

Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Segment by Application

Cancer Treatment Support

Infectious Disease Treatment

Proteinosis Autoimmune Pulmonary Alveolar

Other

Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) significant trends, drivers, influence factors in global and regions.

6. To analyze Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Granulocyte Macrophage Colony Stimulating Factor (GM-CSF).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) industry.

Chapter 3: Detailed analysis of Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Industry Trends Table 2. Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Industry Drivers Table 3. Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Industry Opportunities and Challenges Table 4. Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Industry Restraints Table 5. Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Revenue Share by Company (2021-2026) Table 7. Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Volume Share by Company (2021-2026) Table 9. Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Company Ranking, (2024-2026) & (USD Million) Table 11. Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Key Company Manufacturing Base & Headquarters Table 12. Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Company, Product Type & Application Table 13. Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Injection Table 18. Significant Companies of Inhalation Table 19. Significant Companies of Other Table 20. Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 21. Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Volume by Type (2021-2026) & (K Units) Table 22. Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Volume by Type (2027-2032) & (K Units) Table 23. Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Volume Share by Type (2021-2026) Table 24. Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Volume Share by Type (2027-2032) Table 25. Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Type (2021-2026) Table 29. Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Cancer Treatment Support Table 31. Significant Companies of Infectious Disease Treatment Table 32. Significant Companies of Proteinosis Autoimmune Pulmonary Alveolar Table 33. Significant Companies of Other Table 34. Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 35. Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Volume by Application (2021-2026) & (K Units) Table 36. Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Volume by Application (2027-2032) & (K Units) Table 37. Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Volume Share by Application (2021-2026) Table 38. Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Volume Share by Application (2027-2032) Table 39. Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Application (2021-2026) Table 43. Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Application (2027-2032) Table 44. Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 45. Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales by Region (2021-2026) & (K Units) Table 46. Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Market Share by Region (2021-2026) Table 47. Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales by Region (2027-2032) & (K Units) Table 48. Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Market Share by Region (2027-2032) Table 49. Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Region (2021-2026) Table 52. Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Region (2027-2032) Table 54. Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Market Average Price (US$/Unit) by Region (2021-2026) Table 55. Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Market Average Price (US$/Unit) by Region (2027-2032) Table 56. Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales by Country (2021-2026) & (K Units) Table 59. Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Market Share by Country (2021-2026) Table 60. Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales by Country (2027-2032) & (K Units) Table 61. Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Market Share by Country (2027-2032) Table 62. Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Market Share by Country (2021-2026) Table 64. Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Market Share by Country (2027-2032) Table 66. Nobelpharma Company Information Table 67. Nobelpharma Business Overview Table 68. Nobelpharma Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 69. Nobelpharma Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Product Portfolio Table 70. Nobelpharma Recent Development Table 71. Partner Therapeutics Company Information Table 72. Partner Therapeutics Business Overview Table 73. Partner Therapeutics Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Partner Therapeutics Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Product Portfolio Table 75. Partner Therapeutics Recent Development Table 76. Guangzhou Baiyunshan Pharmaceutical Company Information Table 77. Guangzhou Baiyunshan Pharmaceutical Business Overview Table 78. Guangzhou Baiyunshan Pharmaceutical Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Guangzhou Baiyunshan Pharmaceutical Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Product Portfolio Table 80. Guangzhou Baiyunshan Pharmaceutical Recent Development Table 81. Harbin Pharmaceutical Group Company Information Table 82. Harbin Pharmaceutical Group Business Overview Table 83. Harbin Pharmaceutical Group Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Harbin Pharmaceutical Group Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Product Portfolio Table 85. Harbin Pharmaceutical Group Recent Development Table 86. Hainan Unipul Pharmaceutical Company Information Table 87. Hainan Unipul Pharmaceutical Business Overview Table 88. Hainan Unipul Pharmaceutical Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Hainan Unipul Pharmaceutical Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Product Portfolio Table 90. Hainan Unipul Pharmaceutical Recent Development Table 91. North China Pharmaceutical Company Information Table 92. North China Pharmaceutical Business Overview Table 93. North China Pharmaceutical Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. North China Pharmaceutical Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Product Portfolio Table 95. North China Pharmaceutical Recent Development Table 96. Amoytop Biotech Company Information Table 97. Amoytop Biotech Business Overview Table 98. Amoytop Biotech Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Amoytop Biotech Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Product Portfolio Table 100. Amoytop Biotech Recent Development Table 101. Changchun GeneScience Pharmaceutical Company Information Table 102. Changchun GeneScience Pharmaceutical Business Overview Table 103. Changchun GeneScience Pharmaceutical Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Changchun GeneScience Pharmaceutical Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Product Portfolio Table 105. Changchun GeneScience Pharmaceutical Recent Development Table 106. Key Raw Materials Table 107. Raw Materials Key Suppliers Table 108. Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Distributors List Table 109. Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Customers List Table 110. Research Programs/Design for This Report Table 111. Authors List of This Report Table 112. Secondary Sources Table 113. Primary Sources List of Figures Figure 1. Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Product Image Figure 2. Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value (2021-2032) & (US$ Million) Figure 4. Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales (2021-2032) & (K Units) Figure 5. Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Injection Image Figure 10. Inhalation Image Figure 11. Other Image Figure 12. Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 13. Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Volume Share by Type (2021-2032) Figure 15. Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Type (2021-2032) Figure 18. Cancer Treatment Support Image Figure 19. Infectious Disease Treatment Image Figure 20. Proteinosis Autoimmune Pulmonary Alveolar Image Figure 21. Other Image Figure 22. Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Volume Share by Application (2021-2032) Figure 25. Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Application (2021-2032) Figure 28. Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 29. Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value (2021-2032) & (US$ Million) Figure 33. North America Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value (2021-2032) & (US$ Million) Figure 35. Europe Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value (2021-2032) & (US$ Million) Figure 39. South America Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Value Chain Figure 127. Manufacturing Cost Structure Figure 128. Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • Injection
  • Inhalation
  • Other
Applications
  • Cancer Treatment Support
  • Infectious Disease Treatment
  • Proteinosis Autoimmune Pulmonary Alveolar
  • Other
Companies covered
  • Nobelpharma
  • Partner Therapeutics
  • Guangzhou Baiyunshan Pharmaceutical
  • Harbin Pharmaceutical Group
  • Hainan Unipul Pharmaceutical
  • North China Pharmaceutical
  • Amoytop Biotech
  • Changchun GeneScience Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value (2021-2032)
  4. 1.2.2 Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Volume (2021-2032)
  5. 1.2.3 Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Market Dynamics
  1. 2.1 Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Industry Trends
  2. 2.2 Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Industry Drivers
  3. 2.3 Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Industry Opportunities and Challenges
  4. 2.4 Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Industry Restraints
3 Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Market by Company
  1. 3.1 Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Company Revenue Ranking in 2025
  2. 3.2 Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Revenue by Company (2021-2026)
  3. 3.3 Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Volume by Company (2021-2026)
  4. 3.4 Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Average Price by Company (2021-2026)
  5. 3.5 Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Company Ranking (2024-2026)
  6. 3.6 Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Company Manufacturing Base and Headquarters
  7. 3.7 Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Company Product Type and Application
  8. 3.8 Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Market by Type
  1. 4.1 Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Type Introduction
  2. 4.1.1 Injection
  3. 4.1.2 Inhalation
  4. 4.1.3 Other
  5. 4.2 Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Volume by Type
  6. 4.2.1 Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value by Type
  10. 4.3.1 Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value by Type (2021-2032)
  12. 4.3.3 Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Type (2021-2032)
5 Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Market by Application
  1. 5.1 Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Application Introduction
  2. 5.1.1 Cancer Treatment Support
  3. 5.1.2 Infectious Disease Treatment
  4. 5.1.3 Proteinosis Autoimmune Pulmonary Alveolar
  5. 5.1.4 Other
  6. 5.2 Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Volume by Application
  7. 5.2.1 Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Volume by Application (2021-2032)
  9. 5.2.3 Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Volume Share by Application (2021-2032)
  10. 5.3 Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value by Application
  11. 5.3.1 Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value by Application (2021-2032)
  13. 5.3.3 Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Application (2021-2032)
6 Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Regional Sales and Value Analysis
  1. 6.1 Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales by Region (2021-2032)
  3. 6.2.1 Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales by Region: 2021-2026
  4. 6.2.2 Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales by Region (2027-2032)
  5. 6.3 Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value by Region (2021-2032)
  7. 6.4.1 Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value by Region: 2021-2026
  8. 6.4.2 Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value by Region (2027-2032)
  9. 6.5 Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value (2021-2032)
  12. 6.6.2 North America Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value (2021-2032)
  15. 6.7.2 Europe Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value (2021-2032)
  21. 6.9.2 South America Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Country, 2025 VS 2032
7 Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Country-level Sales and Value Analysis
  1. 7.1 Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales by Country (2021-2032)
  4. 7.3.1 Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales by Country (2021-2026)
  5. 7.3.2 Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales by Country (2027-2032)
  6. 7.4 Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value by Country (2021-2032)
  7. 7.4.1 Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value by Country (2021-2026)
  8. 7.4.2 Global Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Nobelpharma
  2. 8.1.1 Nobelpharma Company Information
  3. 8.1.2 Nobelpharma Business Overview
  4. 8.1.3 Nobelpharma Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Nobelpharma Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Product Portfolio
  6. 8.1.5 Nobelpharma Recent Developments
  7. 8.2 Partner Therapeutics
  8. 8.2.1 Partner Therapeutics Company Information
  9. 8.2.2 Partner Therapeutics Business Overview
  10. 8.2.3 Partner Therapeutics Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Partner Therapeutics Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Product Portfolio
  12. 8.2.5 Partner Therapeutics Recent Developments
  13. 8.3 Guangzhou Baiyunshan Pharmaceutical
  14. 8.3.1 Guangzhou Baiyunshan Pharmaceutical Company Information
  15. 8.3.2 Guangzhou Baiyunshan Pharmaceutical Business Overview
  16. 8.3.3 Guangzhou Baiyunshan Pharmaceutical Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Guangzhou Baiyunshan Pharmaceutical Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Product Portfolio
  18. 8.3.5 Guangzhou Baiyunshan Pharmaceutical Recent Developments
  19. 8.4 Harbin Pharmaceutical Group
  20. 8.4.1 Harbin Pharmaceutical Group Company Information
  21. 8.4.2 Harbin Pharmaceutical Group Business Overview
  22. 8.4.3 Harbin Pharmaceutical Group Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Harbin Pharmaceutical Group Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Product Portfolio
  24. 8.4.5 Harbin Pharmaceutical Group Recent Developments
  25. 8.5 Hainan Unipul Pharmaceutical
  26. 8.5.1 Hainan Unipul Pharmaceutical Company Information
  27. 8.5.2 Hainan Unipul Pharmaceutical Business Overview
  28. 8.5.3 Hainan Unipul Pharmaceutical Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Hainan Unipul Pharmaceutical Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Product Portfolio
  30. 8.5.5 Hainan Unipul Pharmaceutical Recent Developments
  31. 8.6 North China Pharmaceutical
  32. 8.6.1 North China Pharmaceutical Company Information
  33. 8.6.2 North China Pharmaceutical Business Overview
  34. 8.6.3 North China Pharmaceutical Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 North China Pharmaceutical Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Product Portfolio
  36. 8.6.5 North China Pharmaceutical Recent Developments
  37. 8.7 Amoytop Biotech
  38. 8.7.1 Amoytop Biotech Company Information
  39. 8.7.2 Amoytop Biotech Business Overview
  40. 8.7.3 Amoytop Biotech Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Amoytop Biotech Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Product Portfolio
  42. 8.7.5 Amoytop Biotech Recent Developments
  43. 8.8 Changchun GeneScience Pharmaceutical
  44. 8.8.1 Changchun GeneScience Pharmaceutical Company Information
  45. 8.8.2 Changchun GeneScience Pharmaceutical Business Overview
  46. 8.8.3 Changchun GeneScience Pharmaceutical Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Changchun GeneScience Pharmaceutical Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Product Portfolio
  48. 8.8.5 Changchun GeneScience Pharmaceutical Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Value Chain Analysis
  2. 9.1.1 Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Mode & Process
  6. 9.2 Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Distributors
  9. 9.2.3 Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst